• One of the largest US health insurers issues positive coverage for SOZO lymphedema assessment
• Represents 16 million additional covered lives, bringing total to over 301 million
• Expands access to proactive, preventative lymphedema management for cancer survivors

ImpediMed Limited (ASX: IPD) has announced that one of the largest health insurers in the United States has issued positive coverage for CPT Code 93702, recognizing bioimpedance spectroscopy (BIS) as medically necessary for the assessment of lymphedema. This decision supports reimbursement for lymphedema testing using ImpediMed's SOZO Digital Health Platform and represents a significant step forward in the company's mission to prevent breast cancer-related lymphedema. The insurer, which is the largest customer-owned insurer in the US and a licensee of Blue Cross Blue Shield Association in 5 states, provides access to care nationwide through plans in Illinois, Montana, New Mexico, Oklahoma and Texas. This coverage expansion adds 16 million additional covered lives, bringing the total reimbursed coverage for lymphedema testing using SOZO to over 301 million covered lives and 86% coverage nationwide. The announcement builds on recent momentum in insurance coverage, with 3 of the 5 largest US states now having over 90% coverage. ImpediMed's Managing Director Dr. Parmjot Bains commented that these decisions from major insurers greatly enhance the commercial feasibility of implementing SOZO-based lymphedema prevention programs across hospital systems, helping to ensure every at-risk cancer patient has access to proactive, preventative care.

The expanded insurance coverage for SOZO lymphedema assessment represents a significant step forward in ImpediMed's mission to prevent breast cancer-related lymphedema. The company expects these changes to have a meaningful effect on the commercialization of the SOZO platform, as more cancer patients gain access to proactive, preventative care.